Literature DB >> 32347426

Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.

Nora Jacobson1, Julie Horst2, Liam Wilcox-Warren2, Alex Toy2, Hannah K Knudsen3, Randy Brown2, Eric Haram4, Lynn Madden5, Todd Molfenter2.   

Abstract

Medication for opioid use disorder (MOUD) is a key strategy for addressing the opioid use disorder crisis, yet gaps in MOUD provision impede this strategy's benefits. The research reported here sought to understand what distinguishes low- and high-performing organizations in building and using capacity to provide MOUD. As part of a mixed methods MOUD implementation trial, semi-structured telephone interviews were conducted with personnel from low- and high-performing MOUD-providing organizations. Seventeen individuals from 17 organizations were interviewed. Findings demonstrate the importance of individual, organization, and community-level factors in supporting the building and use of MOUD capacity. Low- and high-performing organizations showed different patterns of facilitators and barriers during the implementation process. The key difference between low- and high-performing organizations was the level of organizational functioning. A better understanding of an organization's assets and deficits at the individual, organizational, and community levels would allow decision-makers to tailor their approaches to MOUD implementation.

Entities:  

Year:  2020        PMID: 32347426      PMCID: PMC7578054          DOI: 10.1007/s11414-020-09706-4

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  36 in total

1.  Developing and testing a model to predict outcomes of organizational change.

Authors:  David H Gustafson; François Sainfort; Mary Eichler; Laura Adams; Maureen Bisognano; Harold Steudel
Journal:  Health Serv Res       Date:  2003-04       Impact factor: 3.402

2.  Using organization theory to understand the determinants of effective implementation of worksite health promotion programs.

Authors:  Bryan J Weiner; Megan A Lewis; Laura A Linnan
Journal:  Health Educ Res       Date:  2008-05-09

3.  Adopting the 'cascade of care' framework: an opportunity to close the implementation gap in addiction care?

Authors:  M Eugenia Socías; Nora Volkow; Evan Wood
Journal:  Addiction       Date:  2016-07-13       Impact factor: 6.526

4.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Authors:  Hefei Wen; Jason M Hockenberry; Tyrone F Borders; Benjamin G Druss
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

5.  Why aren't physicians prescribing more buprenorphine?

Authors:  Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2017-04-12

6.  Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.

Authors:  Kelly Alanis-Hirsch; Raina Croff; James H Ford; Kim Johnson; Mady Chalk; Laura Schmidt; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2015-11-06

7.  Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists.

Authors:  Cindy Parks Thomas; Sharon Reif; Sayeda Haq; Stanley S Wallack; Alexander Hoyt; Grant A Ritter
Journal:  Psychiatr Serv       Date:  2008-08       Impact factor: 3.084

8.  Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Authors:  Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Tamara Y Boney; Randall A Hoskinson; Donna Wilson; Ryan McDonald; John Rotrosen; Marc N Gourevitch; Michael Gordon; Marc Fishman; Donna T Chen; Richard J Bonnie; James W Cornish; Sean M Murphy; Charles P O'Brien
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

9.  Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio.

Authors:  Todd Molfenter; Carol Sherbeck; Sandy Starr; Jee-Seon Kim; Mark Zehner; Andrew Quanbeck; Nora Jacobson; Dennis McCarty
Journal:  J Addict Med       Date:  2018 Mar/Apr       Impact factor: 3.702

10.  Factors influencing the adoption of an innovation: an examination of the uptake of the Canadian Heart Health Kit (HHK).

Authors:  Shannon D Scott; Ronald C Plotnikoff; Nandini Karunamuni; Raphaël Bize; Wendy Rodgers
Journal:  Implement Sci       Date:  2008-10-02       Impact factor: 7.327

View more
  4 in total

Review 1.  Expanding access to medications for opioid use disorder through locally-initiated implementation.

Authors:  Jessica J Wyse; Katherine Mackey; Travis I Lovejoy; Devan Kansagara; Anais Tuepker; Adam J Gordon; P Todd Korthuis; Anders Herreid-O'Neill; Beth Williams; Benjamin J Morasco
Journal:  Addict Sci Clin Pract       Date:  2022-06-20

2.  Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample.

Authors:  Jeffrey M Rogers; Kirsten E Smith; Justin C Strickland; David H Epstein
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

3.  Organizational Capacity and Readiness to Provide Medication for Individuals with Co-Occurring Alcohol Use Disorders in Public Mental Health Settings.

Authors:  Katherine E Watkins; Sarah B Hunter; Catherine C Cohen; Isabel Leamon; Brian Hurley; Michael McCreary; Allison J Ober
Journal:  Adm Policy Ment Health       Date:  2021-01-02

4.  Prescribers' satisfaction with delivering medications for opioid use disorder.

Authors:  Hannah K Knudsen; Randy Brown; Nora Jacobson; Julie Horst; Jee-Seon Kim; Hanna Kim; Lynn M Madden; Eric Haram; Todd Molfenter
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-10-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.